Recent Updates
Recently added Catalysts
ANIK Negative Sentiment Score: 30/100

ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders

Key Takeaway: Bragar Eagel & Squire, P.C. is advising Anika Therapeutics investors about an ongoing investigation into potential violations of federal securities laws by the company. The investigation follows Anika's July 2025 announcement regarding its clinical trial of Hyalofast, which reportedly did not meet its primary endpoints. This news led to a significant drop in Anika's stock price by over 27%, raising concerns among investors about their legal rights and potential losses.

Market Sentiment Analysis

CONCERNS & RISKS

  • Ongoing investigation into Anika's potential violations of federal securities laws.
  • Significant stock price drop of 27.42% following the release of clinical trial results.
  • Clinical trial for Hyalofast did not meet pre-specified co-primary endpoints, leading to investor concerns.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK) on behalf of Anika stockholders. Our investigation concerns whether Anika has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On July 30, 2025, Anika issued a press release "announc[ing] topline results from its U.S. pivotal clinical trial of Hyalofast, a resorbable, hyaluronic acid scaffold used in conjunction with autologous bone marrow aspirate concentrate (BMAC) for cartilage repair." The press release stated that "[w]hile Hyalofast demonstrated consistent improvements in treated patients across all measures of pain and function relative to microfracture, the study did not meet its pre-specified co-primary endpoints. The study was likely impacted by both a higher subject dropout rate in the microfracture arm and missed visits during COVID. This resulted in missing data, which reduced the evaluable sample size and complicated the statistical analysis."
On this news, Anika's stock price fell $3.06 per share, or 27.42%, to close at $8.10 per share on July 30, 2025.
If you purchased or otherwise acquired Anika shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What should I do if I lost money in Anika (ANIK) stock?

Contact Brandon Walker or Melissa Fortunato at Bragar Eagel & Squire to discuss your options.

What triggered the drop in Anika's stock price?

Anika's stock fell after it announced that its Hyalofast trial did not meet key endpoints.

Is there a cost to discuss my rights with Bragar Eagel & Squire?

There is no cost or obligation to discuss your legal rights with the firm.

How can I learn more about the claims against Anika?

You can email investigations@bespc.com or call (212) 355-4648 to learn more.

Where is Bragar Eagel & Squire located?

The firm has offices in New York, South Carolina, and California.

Last updated: Jan 26, 2026